223PUsing PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy. (25th November 2018) - Anton, A; Ballok, Z; Bowden, P; Costello, T; Harewood, L; Corcoran, N; Dundee, P; Peters, J; Lawrentschuk, N; Troy, A; Webb, D; Chan, Y; et al.